However, only changes to OAT3 activity have been shown to result in an important change in its elimination, with the OAT3 inhibitor probenecid increasing the AUC of baricitinib by 2-fold.39 FDA has dose reduction recommendations (ie, reduce the dose to half) for baricitinib when it is used with strong transporter (OAT3) inhibitors.39 Another strong OAT3 inhibitor is teriflunomide, which is used for multiple sclerosis. The gene discussed is SLC22A8; the disease is multiple sclerosis.